Radioimmunotherapy (RIT) which links the β-particle-emitting radionuclide 177Lu [t1/2 = 6.7 d; Eβmax = 0.5 MeV (78.6%), Eβmax = 0.38 MeV (9.1%), Eβmax = 0.18 MeV (12.2%)] to anti-EGFR mAbs may be a promising approach for HNSCC, considering that EGFR are frequently overexpressed on tumours (Kalyankrishna and Grandis, 2006). The gene discussed is EGFR; the disease is neoplasm.